Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
| ▸ | CES1 | P23141 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.33 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10481527 | 0.82 | KDM4E (0.45) | MAPTSMN1; SMN2KDM4E | |
| SCHEMBL9796506 | 0.82 | POLB (0.33) | MAPTSMN1; SMN2KDM4ELMNAHPGD | |
| SCHEMBL27731731 | 0.80 | HSP90AB1 (0.43) | IKBKBCES2CES1MAPTSMN1; SMN2 | |
| SCHEMBL11398094 | 0.79 | KEAP1 (0.41) | CES2CES1HTTHDAC1HDAC2 | |
| SCHEMBL11351406 | 0.78 | KDM4E (0.50) | MAPTSMN1; SMN2CLCN2KDM4E | |
| SCHEMBL9722967 | 0.78 | ALDH1A1 (0.42) | IKBKBCES2CES1MAPTSMN1; SMN2 | |
| SCHEMBL9722911 | 0.76 | IKBKB (0.38) | IKBKBCES2CES1MAPTSMN1; SMN2 | |
| SCHEMBL11341393 | 0.75 | KDM4E (0.58) | MAPTSMN1; SMN2HTTKDM4ELMNA | |
| SCHEMBL9722960 | 0.75 | MRGPRX1 (0.37) | IKBKBCES2CES1MAPTSMN1; SMN2 | |
| SCHEMBL3810854 | 0.74 | CLCN2 (0.52) | IKBKBCES2CES1MAPTCLCN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010676-A1 | Stereospecific enrichment of heterocyclic enantiomers | R.T. ALAMO VENTURES I, LLC | 2007-01-11 | — | — | US | disclosed |
| US-20070010552-A1 | Fluorinated heterocyclic compounds and methods of synthesis | R.T. ALAMO VENTURES I, LLC | 2007-01-11 | — | — | US | disclosed |
| EP-1313706-A4 | METHOD FOR SYNTHESIZING FLOSEQUINAN FROM 4-FLUOROANTHRANILIC ACID | R T ALAMO VENTURES I LLC (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1313706-A1 | METHOD FOR SYNTHESIZING FLOSEQUINAN FROM 4-FLUOROANTHRANILIC ACID | R.T. Alamo Ventures I, LLC (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002018343-A1 | METHOD FOR SYNTHESIZING FLOSEQUINAN FROM 4-FLUOROANTHRANILIC ACID | R.T. ALAMO VENTURES I, LLC (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6307050-B1 | CYCLIZATION WITH PHOSGENE; METHYLATION; REACTION WITH DIMSYLSODIUM; REACTION WITH TRIETHYL ORTHOFORMATE IN THE PRESENCE OF PIPERDINE AND ACETIC ACID | R. T. ALAMO VENTURE I LLC | 2001-10-23 | — | — | US | disclosed |
| US-5079264-A | CHEMICAL PROCESS | THE BOOTS CO. PLC (GB) | 1992-01-07 | — | — | US | disclosed |
| EP-0317149-B1 | PROCESS FOR THE SYNTHESIS OF 3-THIO-4-QUINOLONE DERIVATIVES AND INTERMEDIATE COMPOUNDS FOR USE THEREIN, AND THEIR USE AS MEDICAMENTS | The Boots Company PLC (GB) | 1991-11-06 | — | — | EP | disclosed |
| US-5011931-A | For treatment of cardiovascular disorders; hypotensive agents | THE BOOTS COMPANY PLC (GB) | 1991-04-30 | — | — | US | disclosed |
| EP-0343206-A1 | PROCESS FOR THE SYNTHESIS OF 3-THIO-4-QUINOLONE DERIVATIVES AND INTERMEDIATE COMPOUNDS FOR USE THEREIN, AND THEIR USE AS MEDICAMENTS | The Boots Company PLC (GB) | 1989-11-29 | — | — | EP | disclosed |
| WO-1989004827-A1 | PROCESS FOR THE SYNTHESIS OF 3-THIO-4-QUINOLONE DERIVATIVES AND INTERMEDIATE COMPOUNDS FOR USE THEREIN, AND THEIR USE AS MEDICAMENTS | THE BOOTS COMPANY PLC (GB) | 1989-06-01 | — | — | WO | disclosed |
| EP-0317149-A1 | Process for the synthesis of 3-thio-4-quinolone derivatives and intermediate compounds for use therein, and their use as medicaments | The Boots Company PLC (GB) | 1989-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010676-A1 | Stereospecific enrichment of heterocyclic enantiomers | CBR3, CBR1, QDPR | IKBKB 3966/4885CES2 821/4885CES1 1186/4885 |
| US-20070010552-A1 | Fluorinated heterocyclic compounds and methods of synthesis | FDPS, PFAS, AFF4 | IKBKB 1962/4885CES2 403/4885CES1 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.